Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) rose 3.2% during trading on Monday . The company traded as high as $1.68 and last traded at $1.61. Approximately 1,460 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 6,538 shares. The stock had previously closed at $1.56.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered shares of Adlai Nortye from a "buy" rating to a "neutral" rating in a research report on Monday, June 2nd.
Read Our Latest Stock Report on ANL
Adlai Nortye Stock Performance
The stock's 50-day moving average price is $1.55 and its 200 day moving average price is $1.87. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.02.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Stories
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
